close search

Diagnostic accuracy of Molbio Truenat for diagnosis of TB and rifampicin resistance

Tuberculosis (TB) is the second leading cause of death in Papua New Guinea (PNG). GeneXpert MTB/rif a molecular diagnostic for TB has greater sensitivity and specificity than microscopy. However, GeneXpert requires electricity and is costly. New molecular TB diagnostics implementable at the microscopy level are a research priority. There is an urgent need for accurate, battery operated and cheaper TB diagnostics.

The Truenat-MTB/MTB-RIF-Dx reflex assays (Molbio Diagnostics; India) utilise chip-based real-time micro-PCR for detection of TB and rifampicin resistance from samples in 25-120 minutes. They are battery and phone operated devices that can be used in peripheral sites. An accurate point-of-care, portable test such as the Molbio Truenat MTB has the potential to make a significant impact globally, and in countries such as PNG. PNG is one of 4 countries participating in this FIND sponsored multi-country diagnostic accuracy trial, evaluating sensitivity, specificity, and patient important outcomes.

2019 – mid-2020

Doctor Philipp du Cros

Please contact Doctor Philipp du Cros for more information about this project.

EMAIL

Funding
Partners

  • Foundation for Innovative Diagnostics

Partners +
Collaborators

  • PNG Institute of Medical Research,
  • Port Moresby General Hospital,
  • The PNG Central Public Health Laboratory,
  • Victorian Infectious Disease Reference Laboratory,
  • PNG National TB Program

Project
Team

Meet the project team. Together, we are translating research into better health, for all.